

AMENDMENT NO. 2
TO THE OPERATING ENGINEERS LOCAL 501 SECURITY FUND (NEVADA)
SUMMARY PLAN DESCRIPTION AND PLAN DOCUMENT
(Effective January 1, 2023)

This is to certify that the Board of Trustees of the Operating Engineers Local 501 Security Fund, have adopted the following Amendment effective January 1, 2023 to the Summary Plan Description and Plan Document. Specifically, the Fund has added coverage for Autism Spectrum Disorder and applied behavior analysis (ABA) therapy and removed Diplomat as the Plan's exclusive specialty pharmacy specifically for the drug Adynovate to treat hemophilia. Accordingly, the following changes have been made:

INDEMNITY MEDICAL PLAN COVERAGE INFORMATION, a new subsection entitled **Autism Spectrum Disorder** is added on page 51, as follows:

Autism Spectrum Disorder

The diagnosis and treatment of Autism Spectrum Disorder are covered services, which include coverage for Asperger Syndrome and Pervasive Development Disorder. Treatment includes but is not limited to medically necessary applied behavior analysis (ABA), speech, physical and occupational therapies, as well as medically necessary treatment prescribed by a certified or licensed health care professional. Coverage is subject to medical necessity review by Anthem Blue Cross.

EXCLUSIONS AND LIMITATIONS OF THE INDEMNITY MEDICAL PLAN, subsection 15 on page 53 has been modified as follows:

15. milieu therapy, biofeedback, behavior modification, sensitivity training, hypnosis, electro hypnosis, electro sleep therapy, or electro narcosis, with the exception of medically necessary behavior modification services to treat Autism Spectrum Disorder.

IMPORTANT ADDRESSES AND PHONE NUMBERS, page 1 has been updated as follows:


For the section **Prescription Drug Program** under the **Indemnity Plan** coverage and services, Diplomat's address, telephone number and website have been removed.


PRESCRIPTION DRUG PROGRAM FOR ACTIVE EMPLOYEES AND RETIREES UNDER INDEMNITY PLAN, subsection entitled **Injectables and Other Specialty Drugs** on page 62, reference to Diplomat and Adynovate have been removed.-

EXCLUSIONS UNDER THE PRESCRIPTION DRUG PROGRAM, subsection 22 on page 65 has been removed.

CLAIMS AND APPEALS PROCEDURES FOR THE PRESCRIPTION DRUG PROGRAM UNDER THE INDEMNITY PLAN, pages 118 - 128, reference to Diplomat and Adynovate have been removed.

Executed this 6th day of September, 2023.


Chairman


Secretary